FOCALIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FOCALIN (FOCALIN).
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
| Metabolism | Primarily de-esterified by carboxylesterase 1 (CES1) to the inactive metabolite d-ritalinic acid. Hepatic CYP2D6 plays a minor role. |
| Excretion | Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible |
| Half-life | 2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect |
| Protein binding | 90-95% (primarily to albumin) |
| Volume of Distribution | 2.65 L/kg (extensive tissue distribution; crosses blood-brain barrier readily) |
| Bioavailability | Oral immediate-release: 30-40% (due to first-pass metabolism); Extended-release: approximately 30% |
| Onset of Action | Immediate-release: 20-30 min (oral). Extended-release: 30-60 min (oral). Inhaled: not available |
| Duration of Action | Immediate-release: 3-5 hours (attention deficit hyperactivity disorder symptom control). Extended-release: 8-12 hours (smooth symptom control with once-daily dosing) |
| Molecular Weight | 240.3 |
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended. |
| Pediatric use | Age 6-17: initial 2.5 mg twice daily, increase weekly by 2.5-5 mg/day; max 20 mg twice daily or 1 mg/kg/day (whichever less). |
| Geriatric use | Initiate at lowest dose, titrate cautiously; monitor for hypertension and cardiovascular effects. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women; however, animal studies have shown reproductive toxicity. Use only if potential benefit justifies potential risk to the fetus. |
| 2nd trimester | Same as T1; limited human data suggest no increased risk of major malformations, but effects on fetal growth and neurodevelopment are unknown. |
| 3rd trimester | Use in third trimester may be associated with neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and increased risk of preterm delivery. Avoid unless essential. |
Clinical note
Comprehensive clinical and safety monograph for FOCALIN (FOCALIN).
| Placental transfer | Dexmethylphenidate crosses the placenta in animal studies; human data are limited but suggest placental transfer occurs. The exact extent is unknown. |
| Breastfeeding | Dexmethylphenidate is excreted into human breast milk in small amounts. Limited data suggest that infant exposure is low, but potential for adverse effects on growth and development exists. The manufacturer recommends weighing the benefits of breastfeeding against the potential risks. Monitor infant for signs of stimulation (insomnia, irritability, poor feeding). |
■ FDA Black Box Warning
FOCALIN has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Patients should be assessed for risk of abuse before and during therapy.
| Serious Effects |
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIsKnown hypersensitivity to dexmethylphenidate or other methylphenidate productsCurrent or history of glaucomaTics or family history of Tourette's syndromeSevere hypertension, angina, or other significant cardiovascular diseaseHyperthyroidismAgitation or severe anxietyDuring or within 14 days of treatment with MAOIs
| Precautions | Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems., Blood pressure and heart rate increases, psychiatric adverse events (e.g., exacerbation of pre-existing psychosis, mania, aggression), long-term growth suppression in children, seizures, priapism, peripheral vasculopathy including Raynaud's phenomenon. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C: First trimester - Inadequate human data; animal studies show increased fetal resorptions and malformations at high doses. Second and third trimesters - Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia). Avoid use unless potential benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain. Fetal surveillance includes ultrasound for growth restriction and signs of distress. Neonatal monitoring for withdrawal symptoms, including irritability, jitteriness, and feeding difficulties. |
| Fertility Effects | No human data on fertility. Animal studies with methylphenidate (active enantiomer) showed reduced fertility in male rats at high doses. Clinical relevance unknown; potential for reversible impairment of spermatogenesis. |
| High-fat meals may delay absorption of extended-release formulations but do not affect total exposure. Avoid excessive caffeine or stimulants as they may increase cardiovascular side effects. Alcohol should be avoided as it may affect release characteristics and increase CNS depression. |
| Clinical Pearls | Focalin (dexmethylphenidate) is the d-isomer of methylphenidate, offering twice the potency per mg. Use lower doses compared to racemic methylphenidate. Monitor for hypertension, tachycardia, and growth suppression in children. Avoid in patients with glaucoma, motor tics, or a family history of Tourette's syndrome. Abuse potential is high; use with caution in substance use disorder history. |
| Patient Advice | Take Focalin exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Swallow tablets whole; do not crush or chew. For extended-release, do not break, crush, or chew. · Avoid taking Focalin late in the day to prevent insomnia. · Report any chest pain, palpitations, shortness of breath, or fainting immediately. · Inform your doctor if you have a history of heart problems, high blood pressure, seizures, or mental illness. · This medication may impair your ability to drive or operate machinery; avoid until you know how it affects you. · Store at room temperature away from moisture and heat. Keep out of reach of children. |